Literature DB >> 8605325

A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.

X Piao1, A Bernstein.   

Abstract

The murine W and Steel loci encode the Kit receptor tyrosine kinase and its ligand, Steel factor, respectively. Loss of function mutations at either the W or Sl loci lead to a variety of pleiotropic developmental defects, including mast cell deficiency and severe macrocytic anemia. In addition to these loss-of-function mutations, gain-of-function mutations in c-kit, leading to constitutive activation of the Kit receptor, have also been identified in both rodent and human mastocytomas. In this study, we have examined the transforming potential and biologic effects of a point mutation that results in substitution of the aspartic acid at codon 814 in the cytoplasmic kinase domain to tyrosine (D814Y) by introducing either wild-type (Kit) or mutant KitD814Y (KDY) cDNA into an interleukin-3-dependent mast cell line IC2. Stimulation of cells expressing the wild-type Kit receptor (IC2/Kit) with Steel factor in vitro resulted in a short-term growth response, whereas IC2/KDY cells were capable of sustained proliferation in a ligand-independent manner. In addition, expression of KDY resulted in the oncogenic transformation of IC2 cells, as determined by colony formation in vitro in the absence of exogenous growth factors and the formation of mastocytomas in vivo in syngeneic DBA/2 mice. Surprisingly, KDY expression in IC2 cells triggered dramatic changes in cell size and the extent of granulation. In addition, KDY induced the expression of mouse mast cell protease-4 (MMCP-4) and MMCP-6. In contrast, neither of these molecular or cellular changes was observed in IC2/Kit cells treated with Steel factor. These results show that the D814Y mutation in the cytoplasmic kinase domain of the Kit receptor induces ligand-independent mast cell growth in vitro, tumorigenicity in vivo, and mast cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605325

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Activating mutations for the met tyrosine kinase receptor in human cancer.

Authors:  M Jeffers; L Schmidt; N Nakaigawa; C P Webb; G Weirich; T Kishida; B Zbar; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function.

Authors:  Yashoda Sharma; Clinton M Astle; David E Harrison
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

3.  PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal.

Authors:  Michihiro Kobayashi; Yunpeng Bai; Yuanshu Dong; Hao Yu; Sisi Chen; Rui Gao; Lujuan Zhang; Mervin C Yoder; Reuben Kapur; Zhong-Yin Zhang; Yan Liu
Journal:  Stem Cells       Date:  2014-07       Impact factor: 6.277

4.  Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.

Authors:  Raghuveer Singh Mali; Peilin Ma; Li-Fan Zeng; Holly Martin; Baskar Ramdas; Yantao He; Emily Sims; Sarah Nabinger; Joydeep Ghosh; Namit Sharma; Veerendra Munugalavadla; Anindya Chatterjee; Shuo Li; George Sandusky; Andrew W Craig; Kevin D Bunting; Gen-Sheng Feng; Rebecca J Chan; Zhong-Yin Zhang; Reuben Kapur
Journal:  Blood       Date:  2012-07-17       Impact factor: 22.113

5.  Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Authors:  Alison C Macleod; Lillian R Klug; Janice Patterson; Diana J Griffith; Carol Beadling; Ajia Town; Michael C Heinrich
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

6.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.

Authors:  X Piao; R Paulson; P van der Geer; T Pawson; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

7.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 9.  Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.

Authors:  Michihiro Kobayashi; Sisi Chen; Rui Gao; Yunpeng Bai; Zhong-Yin Zhang; Yan Liu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.

Authors:  Glenn Cruse; Dean D Metcalfe; Ana Olivera
Journal:  Immunol Allergy Clin North Am       Date:  2014-03-12       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.